[1]薛 昭,陈 治,张 琴.替莫唑胺联合γ-分次立体定向放疗对肺癌脑转移患者血清骨桥蛋白、细胞角蛋白19片段、鳞状细胞癌抗原水平的影响[J].陕西医学杂志,2025,54(4):492-496,506.[doi:DOI:10.3969/j.issn.1000-7377.2025.04.011]
　XUE Zhao,CHEN Zhi,ZHANG Qin.Effects of Temozolomide combined with γ-fractionated stereotactic radiotherapy on serum levels of OPN,CYFRA21-1 and SCC in lung cancer patients with brain metastases[J].,2025,54(4):492-496,506.[doi:DOI:10.3969/j.issn.1000-7377.2025.04.011]
点击复制

替莫唑胺联合γ-分次立体定向放疗对肺癌脑转移患者血清骨桥蛋白、细胞角蛋白19片段、鳞状细胞癌抗原水平的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年4期
页码:
492-496,506
栏目:
临床研究
出版日期:
2025-04-05

文章信息/Info

Title:
Effects of Temozolomide combined with γ-fractionated stereotactic radiotherapy on serum levels of OPN,CYFRA21-1 and SCC in lung cancer patients with brain metastases
作者:
薛 昭1; 陈 治1; 张 琴2
(1.陕西中医药大学附属咸阳市第一人民医院肿瘤科,陕西 咸阳 712000; 2.西安工会医院检验科,陕西 西安 710100)
Author(s):
XUE Zhao1; CHEN Zhi1; ZHANG Qin2
(1.Oncology Department,The First People's Hospital of Xianyang,Xianyang 712000,China; 2.Clinical Laboratory,Xi'an Trade Union Hospital,Xi'an 710100,China)
关键词:
替莫唑胺;  γ-分次立体定向放疗;  肺癌;  脑转移;  生存
Keywords:
Temozolomide;  γ-fractionated stereotactic radiotherapy;  Lung cancer;  Brain metastases;  Survival
分类号:
R 739.41
DOI:
DOI:10.3969/j.issn.1000-7377.2025.04.011
文献标志码:
A
摘要:
目的:探讨肺癌脑转移患者采用γ-分次立体定向放疗联合替莫唑胺进行治疗的疗效。方法:采用临床随机试验,选取102例肺癌脑转移患者开展临床研究,采用统计学软件生成随机数字表将患者分为联合治疗组和对照组各51例,联合治疗组采用替莫唑胺联合γ-分次立体定向放疗方法治疗,对照组采用γ-分次立体定向放疗,比较两组治疗前后血清骨桥蛋白(OPN)、细胞角蛋白19片段(CYFRA21-1)、鳞状细胞癌抗原(SCC)的变化及近期疗效、免疫指标变化,并计算两组患者的生存时间。结果:治疗前,联合治疗组与对照组患者的 OPN、CYFRA21-1、SCC 及 CD3+、CD4+、CD8+ 水平进行对比分析,两组之间比较无统计学差异(P>0.05); 联合治疗组与对照组患者在治疗后的 OPN、CYFRA21-1、SCC 水平与本组治疗前对比显著降低(均P<0.05),且联合治疗组较对照组降低更为明显(P<0.05); 同时,两组患者 CD3+、CD4+ 水平显著降低(均P<0.05),CD8+ 水平显著升高(P<0.05),联合治疗组治疗后的 CD3+、CD4+ 高于对照组(均P<0.05); 治疗过程中,联合治疗组患者的恶心、呕吐、白细胞减少、血小板减少发生的严重程度高于对照组(均P<0.05),两组患者腹泻、放射性皮炎、口腔黏膜炎、肝肾功能损伤发生程度比较,差异无统计学意义(均P>0.05); 联合治疗组的总体疗效优于对照组(P<0.05); 对两组患者连续随访24个月,联合治疗组的中位生存时间15.0个月、对照组的中位生存时间13.0个月,联合治疗组的中位生存时间长于对照组(χ2=7.252,P<0.05)。结论:γ-分次立体定向放疗联合替莫唑胺方案治疗肺癌脑转移的效果优于单独的γ-分次立体定向放疗,并且更有利于延长生存时间,但应注意毒副反应的应对处理。
Abstract:
Objective:o investigate the clinical effect of temozolomide combined with γ-fractionated stereotactic radiotherapy on lung cancer patients with brain metastases.Methods:A clinical randomized trial was conducted to investigate 102 patients with brain metastases from lung cancer.Using statistical software to generate a random number table,the patients were divided into a combined treatment group and a control group,with 51 patients in each.The combined treatment group received temozolomide combined with gamma-fractionated stereotactic radiotherapy,while the control group received gamma-fractionated stereotactic radiotherapy alone.Changes in serum osteopontin(OPN),cytokeratin 19 fragment(CYFRA21-1),squamous cell carcinoma antigen(SCC)before and after treatment,as well as short-term efficacy and immune indicators,were compared between the two groups.Additionally,the survival time of patients in both groups was calculated.Results:Before treatment,a comparative analysis of OPN,CYFRA21-1,SCC,and CD3+,CD4+,CD8+ levels was conducted between the combined treatment group and the control group,revealing no significant differences between the two groups(P>0.05).After treatment,the levels of OPN,CYFRA21-1,and SCC in both groups were significantly reduced compared to their pre-treatment levels(all P<0.05),with a more pronounced decrease observed in the combined treatment group compared to the control group(P<0.05).Additionally,the levels of CD3+ and CD4+ significantly decreased in both groups(all P<0.05),while the level of CD8+ significantly increased(P<0.05).Notably,the post-treatment levels of CD3+ and CD4+ in the combined treatment group were higher than those in the control group(all P<0.05).During treatment,the severity of nausea,vomiting,leukopenia,and thrombocytopenia was higher in the combined treatment group compared to the control group(all P<0.05).However,there was no statistically significant difference in the severity of diarrhea,radiodermatitis,oral mucositis,and liver and kidney function damage between the two groups(all P>0.05).The overall efficacy was better in the combined treatment group compared to the control group(P<0.05).After 24 months of continuous follow-up,the median survival time was 15.0 months in the combined treatment group and 13.0 months in the control group,with the median survival time being longer in the combined treatment group compared to the control group(χ2=7.252,P<0.05).Conclusion:The combination of γ-fractionated stereotactic radiotherapy and temozolomide for the treatment of brain metastases from lung cancer is more effective than γ-fractionated stereotactic radiotherapy alone and is more conducive to prolonging survival time.However,attention should be paid to managing and addressing the toxic and adverse reactions.

参考文献/References:

[1] 刘宗超,李哲轩,张阳,等.2020全球癌症统计报告解读[J].肿瘤综合治疗电子杂志,2021,7(2):1-13.
[2] 李璐璐,卢峰,韦士勤,等.放疗联合重组人血管内皮抑素治疗肺癌脑转移瘤合并脑水肿的疗效评估[J].中国实用神经疾病杂志,2024,27(8):998-1002.
[3] 朱以香,王洁.肺癌脑转移的药物治疗进展[J].中国肿瘤临床与康复,2024,31(7):397-406.
[4] 周善炎,陈英耀,徐子安,等.肿瘤电场治疗联合替莫唑胺治疗胶质母细胞瘤的快速卫生技术评估[J].中国医院管理,2024,44(10):49-54.
[5] 中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)[J].中华医学杂志,2021,101(23):1725-1757.
[6] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90,111.
[7] 潘宏铭,耿宝琴.肿瘤化疗的毒副反应和防治[M].上海:上海科学技术出版社,2001:214.
[8] 阿丽亚?奥斯曼,刘俊远,帕提古力?阿尔西丁.局限期小细胞肺癌患者生存及发生脑转移的影响因素分析[J].国际呼吸杂志,2024,44(3):294-304.
[9] TAKAYAMA Y,YANO J,SEIKE R,et al.Efficacy of chemoimmunotherapy in NSCLC patients with brain metastasis with or without prior brain radiotherapy[J].Anticancer Research:International Journal of Cancer Research and Treatment,2022,42(10):4805-4812.
[10] 杨海林,白英伟,魏少贤,等.贝伐珠单抗联合放疗治疗肺癌脑转移的临床疗效及对患者免疫功能、肿瘤标志物的影响[J].癌症进展,2022,20(18):1892-1895,1898.
[11] 余双,杨树仁,王海兰,等.替莫唑胺联合全脑同期局部推量调强放疗治疗肺癌脑转移的效果及安全性分析[J].上海医药,2022,43(24):26-30.
[12] 陈淑,胡莉,王宝红.IMRT放疗与联合替莫唑胺或司莫司汀化疗对恶性脑胶质瘤术后患者疗效及预后的影响[J].贵州医药,2022,46(1):47-49.
[13] 田碧,孙旭东,马建,等.恶性脑胶质瘤术后放疗与同步放化疗的疗效比较及影响因素分析[J].现代肿瘤医学,2022,30(4):607-612.
[14] 朱淑敏,马进,耿玉兰,等.血清OPN、Wip1、HSP90α与晚期非小细胞肺癌患者一线化疗敏感性和预后的关系[J].现代生物医学进展,2023,23(24):4740-4745.
[15] JAFARI-KASHI A,RAFIEE-POUR H A,SHABANI-NOOSHABADI M.A new strategy to design label-free electrochemical biosensor for ultrasensitive diagnosis of CYFRA 21-1 as a biomarker for detection of non-small cell lung cancer[J].Chemosphere:Environmental Toxicology and Risk Assessment,2022,301(8):1-8.
[16] SUN A W.Clinical role of serum tumor markers SCC,NSE,CA125,CA19-9,and CYFRA21-1 in patients with lung cancer[J].Laboratory Medicine,2023,54(6):638-645.
[17] 高晖,黄凤仙,王海鹏,等.EGFR突变与替莫唑胺联合IGRT大分割放射治疗非小细胞肺癌脑转移瘤疗效的相关性[J].现代生物医学进展,2022,22(16):3081-3085.
[18] 李盈盈,冯黎黎,韩峰.胶质母细胞瘤对替莫唑胺耐药机制的研究进展[J].南京医科大学学报,2024,44(5):688-697.
[19] 郭静,杜珍武,杨静,等.肺癌患者外周血淋巴细胞亚群计数水平的比较分析[J].中国实验诊断学,2024,24(9):1035-1040.
[20] 杨麒麟,魏敏,杨霞,等.重组人血管内皮抑制素联合脑部放疗与单纯放疗治疗实体肿瘤脑转移的疗效及预后[J].中国实用神经疾病杂志,2024,27(8):990-997.
[21] 何锋,王小英,刘宁,等.胸腔镜肺癌根治术对非小细胞肺癌患者外周血T淋巴细胞亚群的影响及临床意义[J].中国免疫学杂志,2022,38(6):725-730.
[22] 万畅,庞静丹,吴正升,等.非小细胞肺癌脑转移免疫微环境、临床病理特征分析[J].临床与实验病理学杂志,2023,39(11):1316-1321.
[23] 张秀淋,李淑霞,欧阳鹏.替莫唑胺与放疗对肺癌脑转移临床治疗效果、免疫功能改善及并发症发生情况的影响[J].实用癌症杂志,2020,35(8):1318-1322.
[24] 俞岑明,石佑萌,刘怡,等.LncRNA MALAT1对非小细胞肺癌患者脑转移的预测价值[J].分子诊断与治疗杂志,2022,14(11):1858-1861,1866.

备注/Memo

备注/Memo:
[基金项目]陕西省自然科学基金资助项目(2021-JC-QN-0897); 陕西省咸阳市重点研发计划项目(2020K02-105)
更新日期/Last Update: 2025-04-07